Key Highlights

● SELLAS' Phase 3 REGAL trial reached its final-analysis event count.

● Results are expected later this quarter.

● The trial tests galinpepimut-S as a maintenance treatment.

● Reaching an event count precedes, but does not reveal, trial results.

SELLAS Life Sciences (NASDAQ:SLS) slid after the biotech said its Phase 3 REGAL trial had reached the event count needed for its final analysis, in acute myeloid leukemia, with results now due later this quarter. The milestone brings SELLAS closer to the readout of a late-stage trial of its lead drug, a key event for the company.

The stock fell steeply during the session on the news.

What an Event Count Means

Many cancer trials are designed to reach a set number of events, typically a specific outcome such as a patient's death in a survival trial, before the final analysis is run. Reaching the target number means enough data has been collected to judge whether the treatment works compared with the control group.

Hitting the event count does not reveal the results; it simply starts the process of locking the database, analyzing the data and announcing the outcome. For investors, that creates a binary moment, and some choose to reduce exposure ahead of such readouts.

What SELLAS Does

SELLAS Life Sciences is a late-stage biotech developing cancer immunotherapies. Its lead candidate, galinpepimut-S, is designed to train the immune system to target a protein found in many cancers, including acute myeloid leukemia.

The REGAL trial is testing the drug as a maintenance treatment in patients with AML who have achieved a second remission, an aggressive blood cancer where relapsed patients have limited options.